Ferring Pharmaceuticals Acquires Licensing Rights for Elobixibat from Albireo AB
-Ferring Pharmaceuticals (Ferring) and Albireo AB (Albireo) announced today that they have signed a license agreement under which Ferring has…
Ferring Pharmaceuticals donates $10 million to the Salk Institute for Biological Studies
-Ferring Pharmaceuticals, a global, specialty biopharmaceuticals company, has donated $10 million to support research at the Salk Institute…
New data show that FIRMAGON® (degarelix) is non-inferior to the combination of goserelin plus bicalutamide at reducing prostate volume in patients with advanced hormone-dependent prostate cancer while offering better relief from lower urinary tract symptoms
-Two new studies presented at the 27th Annual European Association of Urology (EAU) Congress reported that…
Ferring announces new million euro educational initiative with International Federation of Fertility Societies (IFFS) and Elsevier
-World leader in fertility treatments, Ferring Pharmaceuticals, announced today at the 2012 Updates in Infertility Treatment (UIT) meeting that…
Archives Press release 2012
Archives Press release 2012